The increasing recognition of cyclic vomiting syndrome (CVS) in adults prompted the
development of these evidence‐based guidelines on the management of CVS in adults …

Purpose This review summarizes the recommendations for the prophylaxis of nausea and
vomiting in adults receiving highly emetogenic chemotherapy (HEC) which includes …

Despite the considerable progress achieved in the last 30 years, vomiting and, especially,
nausea, continue to be two of the most distressing side-effects of cancer chemotherapy. In …

Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated
with anticancer treatment that can have a significant adverse impact on patient health …

Summary Background Aprepitant (Emend, Merck Sharp & Dohme Ltd, Haarlem, the
Netherlands), a neurokinin‐1 receptor antagonist, prevents vomiting in a range of …

Introduction Laparoscopic sleeve gastrectomy (LSG) is associated with postoperative
nausea and vomiting (PONV). We aimed to compare the effects of aprepitant on the …

To examine pharmacologic and clinical characteristics of neurokinin 1 (NK1)-receptor
antagonists (RAs) for preventing chemotherapy-induced nausea and vomiting (CINV) …

Netupitant is a new, selective NK1 receptor antagonist under development for the prevention
of chemotherapy‐induced nausea and vomiting. Two studies were conducted to evaluate …

Neurokinin receptors belong to the GPCRs family and are ubiquitously expressed
throughout the nervous and immune systems. Neurokinin receptors in coordination with …

Chemotherapy-induced nausea and vomiting (CINV) remains one of the most debilitating
toxicities associated with cancer treatment. In recent decades, significant strides have been …